It was a great pleasure to catch up with Susan Hutchinson (Orange County Migraine & Headache Center, Irvine, CA, USA) to discuss her recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors, for the prevention and treatment of migraine.
The abstract entitled: ‘Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What are the unmet needs in the treatment of migraine in adults with cardiovascular risk factors? (0:13)
- Could you give us a brief overview of the clinical development of small molecule CGRP receptor antagonists for migraine prevention and treatment? (1:01)
- Could you please describe your recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors? (1:40)
- What were the findings of this study and what are their implications for clinical practice? (3:32)
- What does the future migraine treatment landscape look like? (4:46)
Disclosures: In the past two years, Susan Hutchinson has served as a consultant/advisory board member for Alder/Lundbeck, Allergan/AbbVie, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, Novartis, Teva, Theranica, Upsher-Smith; and is on the speaker’s bureau for AbbVie, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Teva, Theranica and Upsher-Smith.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Andrew Blumenfeld, AHS 2021: Combination use of OnabotulinumtoxinA and CGRP mAbs for Chronic Migraine
We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine. The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at […]
Richard Lipton, AHS 2021: COURAGE Study Results
touchNEUROLOGY met with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the COURAGE study results investigating the Migraine Buddy Application. The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!